Phase I Trial of Icotinib, a novel epidermal growth factor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer

Tumor gene mutations and messenger RNA expression: correlation with clinical response to Icotinib hydrochloride in non-small cell lung cancer